EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Use of Pegylated Interferon Alpha-2a in Cutaneous T-cell Lymphoma: A Retrospective Case Collection

Janika Gosmann, Rudolf Stadler, Koen D Quint, Ralf Gutzmer, Maarten H Vermeer

Acta Dermato-Venereologica · 30.10.2023 · 103 · adv10306

DOI: 10.2340/actadv.v103.10306 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Acta Dermato-Venereologica, online erschienen am 30.10.2023. Verfasst von Janika Gosmann und 4 weiteren Autor:innen. Beteiligte Einrichtung: University Department for Dermatology, Venereology, Allergology and Phlebology Skin Cancer Center, Johannes Wesling Medical Center Minden, Ruhr Unive…. Hauptthemen laut MEDLINE: Lymphoma, T-Cell, Cutaneous, Skin Neoplasms. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mycosis fungoides and Sézary syndrome are rare and largely incurable types of cutaneous T-cell lymphoma with limited therapeutic options. In 1984 Bunn et al. reported that interferon alpha is an efficient monotherapy in cutaneous T-cell lymphoma and 14 years later it was shown in a prospective, randomized trial that a combination of interferon alpha and psoralen plus ultraviolet A therapy (PUVA) is most efficient in the treatment of cutaneous T-cell lymphoma. Since then interferon alpha as single agent or, most often, in combination with phototherapy and/or retinoids has been integrated as standard of care in cutaneous T-cell lymphoma guidelines worldwide. However, production of interferon alpha was discontinued recently worldwide and pegylated interferon alpha-2a (PEG-IFNα) has been used as an alternative therapy. In contrast to numerous interferon alpha studies, only a few studies focusing on PEG-IFNα are available. Therefore, the aim of this study was to conduct a retrospective data collection to report on the efficacy, adverse events and therapy regimens of PEG-IFNα in cutaneous T-cell lymphoma. In 28 patients with cutaneous T-cell lymphoma treated in Germany and in the Netherlands, 36% of patients achieved complete remission, 36% partial remission and 29% stable disease. Eighteen percent of patients developed adverse events during therapy, which led to the discontinuation of PEG-IFNα therapy in 2 patients. The most common concomittant therapies were oral PUVA phototherapy and local radiotherapy. In conclusion, PEG-IFNα, especially in combination with skin-directed therapies, is an effective treatment option for cutaneous T-cell lymphoma in clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, T-Cell, CutaneousSkin NeoplasmsHumansInterferon-alphaPolyethylene GlycolsRetrospective Studies

Substanzen

Interferon-alphaPolyethylene Glycols

Autor:innen und Institutionen

  • University Department for Dermatology, Venereology, Allergology and Phlebology Skin Cancer Center, Johannes Wesling Medical Center Minden, Ruhr University Bochum, Minden, Germany.
  • University Department for Dermatology, Venereology, Allergology and Phlebology, Skin Cancer Center, Johannes Wesling Medical Center Minden, Ruhr University Bochum, Minden, Germany. rudolf.stadler@ruhr-uni-bochum.de.
  • Department of Dermatology of the Leiden University medical Center (LUMC), Leiden, the Netherlands.

Zitieren

APA

Gosmann, J., Stadler, R., Quint, K. D., Gutzmer, R., & Vermeer, M. H. (2023). Use of Pegylated Interferon Alpha-2a in Cutaneous T-cell Lymphoma: A Retrospective Case Collection. Acta Dermato-Venereologica, 103, adv10306. https://doi.org/10.2340/actadv.v103.10306

Vancouver

Gosmann J, Stadler R, Quint KD, Gutzmer R, Vermeer MH. Use of Pegylated Interferon Alpha-2a in Cutaneous T-cell Lymphoma: A Retrospective Case Collection. Acta Dermato-Venereologica. 2023;103:adv10306. doi:10.2340/actadv.v103.10306

BibTeX
@article{Gosmann2023,
  author = {Gosmann, Janika and Stadler, Rudolf and Quint, Koen D and Gutzmer, Ralf and Vermeer, Maarten H},
  title = {Use of Pegylated Interferon Alpha-2a in Cutaneous T-cell Lymphoma: A Retrospective Case Collection},
  journal = {Acta Dermato-Venereologica},
  year = {2023},
  volume = {103},
  pages = {adv10306},
  doi = {10.2340/actadv.v103.10306}
}
Kostenlos starten →